Vésale Bioscience receives €1.8M grant from European Innovation Council for PhageDiag project
Summary
Grant will allow V\xe9sale Bioscience to develop phage therapy diagnostic platform in global fight against multidrug-resistant infections Namur, Belgium, January 17, 2023 V\xe9sale Bioscience, a leading company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, announces today it has received 1.8M ($1.9M) in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using artificial intelligence that enables decentralized diagnostics and personalized treatment. The EIC Accelerator jury highlighted in its decision that: V\xe9sale Bioscience is tackling the AMR global issue by developing a clear diagnosis that allows a personalized phage treatment which potentially gives a higher rate of success. PhageDiag consists of a basic test kit (a disposable well plate with reagents), a high-performance luminometer and a dedicated software that offers the best matching phage combination to treat the patient, using artificial intelligence. This approach requires a rapid diagnostic test to identify the pathogens involved in the infection and choose the phages that would be active on them, said Dr Johan Quintens, chief scientific officer at V\xe9sale Bioscience. Its team includes world-renowned experts, who have helped achieve major advances in the development of research and production process design.